Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

New drug targets for multiple myeloma

Research investigators have identified molecular changes in multiple myeloma cells that activate an important biological pathway associated with cell growth and survival, thereby revealing potential new targets for drugs to treat this cancer.

13 Aug 2007

Mortality rates from pulmonary fibrosis will continue to rise

Mortality rates from pulmonary fibrosis (PF) have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado.

2 Aug 2007

Obesity a risk factor for multiple myeloma

An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health.

20 Jul 2007

Obesity a risk factor for multiple myeloma

An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women’s Hospital, Harvard Medical School, and Harvard School of Public Health.

19 Jul 2007

Myeloma cancer drug gets the green light from the EU

The European Union has given the green light to a drug which doubles the survival rates for people with myeloma.

21 Jun 2007

Foie gras can speed amyloid development

University of Tennessee Graduate School of Medicine professor and researcher Alan Solomon, M.D., director of the Human Immunology and Cancer/Alzheimer's Disease and Amyloid-Related Disorders Research Program, led a team that discovered a link between foie gras prepared from goose or duck liver and the type of amyloid found in rheumatoid arthritis or tuberculosis.

19 Jun 2007

$Transplantation does not benefit patients with refractory myeloma$

Transplantation does not benefit patients with refractory myeloma

A study, led by Dr. Joan Blad, researcher of the Haematooncology Group of Hospital Cl'nic-IDIBAPS (Barcelona), in collaboration with Dr. Laura Rosi'ol, researcher of the same group, assessed the efficiency in terms of response and survival of autologous bone marrow transplantation in patients suffering from refractory myeloma previously having undergone high-dose chemotherapy (HDT).

5 Jun 2007

Revlimid may change the way physicians treat multiple myeloma

Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG 4A03) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.

5 Jun 2007

Scientists develop a more human-like mouse model of cancer

A team led by Dana-Farber Cancer Institute scientists has developed a more human-like mouse model of cancer they say will aid the search for cancer-causing genes and improve the predictive value of laboratory drug testing.

28 May 2007

FDA approves VELCADE plus DOXIL combination for multiple myeloma

Ortho Biotech Products has announced the U.S. Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in combination with VELCADE (bortezomib) for Injection to treat patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy.

23 May 2007

Patients with myelodysplastic syndromes treated with Revlimid are living longer and remaining transfusion independent

New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented by Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, at the 9th International Symposium on MDS currently taking place in Florence, Italy.

18 May 2007

Multiple myeloma dexamethasone / lenalidomide trial closes

The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.

16 May 2007

Novel targeted therapy effectively treats acute leukemia

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.

20 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007

Chaetocin shows promise as a new anti-myeloma agent

Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.

16 Apr 2007

Lower doses of dexamethasone for multiple myeloma recommended

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma.

5 Apr 2007

Multiple myeloma trial has shows significant improvement in survival

Mayo Clinic Cancer Center has announced that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.

5 Apr 2007

Recognition for cancer researchers

World-class cancer researchers whose science has significantly contributed to progress in the fight against cancer will be recognized April 14-18, 2007, by the American Association for Cancer Research (AACR) at its 2007 Annual Meeting in Los Angeles, Calif.

3 Apr 2007